2.00
0.00 (0.00%)
| Previous Close | 2.00 |
| Open | 2.01 |
| Volume | 549,000 |
| Avg. Volume (3M) | 10,004,887 |
| Market Cap | 4,256,868,608 |
| Price / Earnings (TTM) | 28.57 |
| Price / Sales | 2.88 |
| Price / Book | 0.940 |
| 52 Weeks Range | |
| Earnings Date | 30 Mar 2026 |
| Profit Margin | 8.42% |
| Operating Margin (TTM) | 11.23% |
| Diluted EPS (TTM) | 0.070 |
| Quarterly Revenue Growth (YOY) | -0.80% |
| Quarterly Earnings Growth (YOY) | 11,430.90% |
| Total Debt/Equity (MRQ) | 33.65% |
| Current Ratio (MRQ) | 1.67 |
| Operating Cash Flow (TTM) | 373.99 M |
| Levered Free Cash Flow (TTM) | 188.26 M |
| Return on Assets (TTM) | 1.98% |
| Return on Equity (TTM) | 5.92% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (HK) | Mixed | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | VIVA BIOTECH | - | - |
AIStockmoo Score
| Analyst Consensus | 0.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 1.5 |
| Technical Oscillators | -2.0 |
| Average | -0.63 |
Similar Stocks
| Stock | Market Cap | DY | P/E (TTM) | P/B |
|---|---|---|---|---|
| VIVA BIOTECH | 4 B | - | 28.57 | 0.940 |
| CSTONE PHARMA-B | 14 B | - | - | 27.87 |
| CKLIFE SCIENCES | 7 B | - | - | 1.88 |
| ANTENGENE-B | 3 B | - | - | 2.84 |
| SINOMAB BIO-B | 2 B | - | - | 4.23 |
| IMMUNOTECH-B | 2 B | - | - | 20.15 |
|
Viva Biotech Holdings is engaged in providing the structure-based drug discovery services to biotechnology and pharmaceutical customers for their pre-clinical stage drug development. The company operates in three reportable segments, Drug Discovery Services providing structure-based drug discovery services to biotechnology and pharmaceutical customers for their pre-clinical stage drug development; Contract Development Manufacture Organisation providing contract development and manufacturing services for small molecule APIs and intermediates and trading of APIs, intermediates and formulations; and commercialisation services; and Viva BioInnovator making strategic investments in biotechnology startup companies. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 43.29% |
| % Held by Institutions | 7.84% |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |